Last updated: February 27, 2026
What is the Origin and Classification of NDC 23155-0929?
NDC 23155-0929 is a marketed drug product. According to the FDA's National Drug Code (NDC) directory, this code corresponds to a pharmaceutical product within a specific therapeutic class. Based on available records, it aligns with [specific drug name], indicated primarily for [indication or use].
Market Overview
Therapeutic Area and Competitive Landscape
The product operates within the [therapeutic class, e.g., oncology, immunology, neurology]. This class has experienced steady growth, driven by [key factors such as rising prevalence, new indications, or increased adoption].
Main competitors include [list top 3-5 drugs]. These competitors vary in administration route (oral, injectable), patent status, and pricing policies.
Market Size and Growth Trends
The global market for [therapeutic area] was valued at approximately $X billion in 2022. Expected compound annual growth rate (CAGR) over the next five years ranges from Y% to Z%, influenced by factors like [bio-similar pipeline, regulatory approvals, reimbursement trends].
In the U.S., the specific product segment captured $A million in sales in 2022, with an estimated B% market share.
Regulatory and Patent Environment
The product's patent status significantly influences its price and market exclusivity. As of [date], the patent for this drug [is still active/has expired], which impacts market competition and pricing strategies.
FDA approvals, including potential expanded indications or biosimilar entries, could further shape the growth trajectory.
Price Trends and Projections
Current Pricing Landscape
The average wholesale price (AWP) for [the drug] is around $X per unit/ dose. Prices vary based on formulation, dosage, and packaging.
Pricing comparison:
| Product |
Price per unit |
Approval Year |
Patent Status |
Market Share (2022) |
| NDC 23155-0929 |
$X |
YYYY |
Patent active/inactive |
B% |
| Competitor 1 |
$Y |
YYYY |
Patent status |
C% |
| Competitor 2 |
$Z |
YYYY |
Patent status |
D% |
Future Price Projections (2023–2027)
Several factors will impact pricing over the forecast period:
- Patent expiration: Expected in [year]. Post-expiry, prices may decline by [estimated percentage] due to generic entry.
- Market competition: Biosimilar or generic versions could reduce prices by [range, e.g., 20-40%] within [timeframe].
- Reimbursement policies: Payer negotiations and formulary placements can alter effective patient prices.
Based on historical trends and competitive dynamics, prices are projected as follows:
| Year |
Estimated Price per Unit |
Remarks |
| 2023 |
$X |
Current price |
| 2024 |
$Y (decrease by 10-15%) |
Post-patent expiration or increased competition |
| 2025 |
$Z (further decrease) |
Market stabilization after generic entry |
Impact of Biosimilar Entry
If the product is a biologic, biosimilar entry can lead to price reductions of 30-50% within 2–3 years of approval, as seen with similar biologics such as [reference biosimilar examples].
Key Market Drivers and Risks
Drivers include:
- Rising disease prevalence.
- Regulatory approvals expanding indications.
- Reimbursement coverage and favorable formulary status.
Risks include:
- Patent challenges.
- Regulatory delays for biosimilars.
- Pricing pressures from payers.
Key Takeaways
- The product aligns with a growing therapeutic class, with stable or increasing market share.
- Current pricing remains steady; significant reductions are expected after patent expiration, unless sustained by strong patent protection or exclusivities.
- Biosimilar competition and regulatory developments are the primary factors influencing future prices.
- The overall market growth and competitive landscape suggest moderate downward pressure on prices over the next 3–5 years.
Frequently Asked Questions
1. What factors most impact the price of NDC 23155-0929?
Patent status, market competition, regulatory approvals, and reimbursement policies.
2. When is patent expiration expected, and how will it affect pricing?
Patent expiration is projected for [year], likely leading to a price decrease of [estimated percentage] due to generic or biosimilar competition.
3. Are biosimilars expected to enter the market soon?
If the drug is biologic-based, biosimilar entry could occur within 2–3 years post-approval, influencing pricing.
4. How does the current market share compare to competitors?
The product holds approximately B% of the market, competing with others holding [percentages].
5. What is the outlook for reimbursement levels?
Reimbursement levels are expected to remain stable but could tighten if newer, less expensive competitors enter.
References
- U.S. Food and Drug Administration. (2023). NDC Directory. https://www.fda.gov/drugs/ndc-directory
- IQVIA. (2022). National Prescription Audit.
- EvaluatePharma. (2023). World Preview 2023.
- FDA. (2022). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars
- MarketResearch.com. (2023). Therapeutic Area Industry Reports.
